Onconova Therapeutics Inc.

Onconova, a privately held Delaware Corporation, is developing innovative products for combating cancer. We are creating novel Solutions for Oncology by combining conventional pharmaceutical science (a small molecule approach) with the latest genomic and genetic technologies for drug discovery and development.

Anticipated Milestones

Clinical data to be presented at the 2006 ASCO conference. Phase II studies expected in the second half of 2006.

Human testing in 2006 leading to expedited approval of Ex-RAD™ is expected in 2008. This program is developed under Protective Agent Rule.

Advance of a lead compound to full development leading to an IND submission in 2007.

Recent News

Phase I clinical trials (at three centers in USA) for lead anticancer compound ON 01910.Na advancing towards proof of concept.

The radiation protection drug Ex-RAD™ has been supported by funding from the US Govt. More than $5 Million in funding secured to date.

New compounds, uniquely capable of targeting the T315I mutation of Gleevec™ resistant Leukemia patients, have been developed.